An interventional study of Deep Brain Reorienting (DBR) and Treatment-as-usual (TAU) in PTSD and Post-traumatic Stress Disorder (PTSD), sponsored by The Royal Ottawa Mental Health Centre. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by The Royal Ottawa Mental Health Centre · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies in Stress Disorders, Post-Traumatic with a site in Canada — 33 open to participants now, 41 under way, 2 of them phase 3. Stress Disorders, Post-Traumatic · Canada.
Among the 126 studies in Stress Disorders, Post-Traumatic with a site in Canada, this one is the 86th largest by planned enrollment of the 112 interventional ones that give a count, is one of 16 that started in 2026, is one of 83 with no phase, reaches primary completion later than 27 of the 40 other live ones, and was the 126th registered.
2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 603 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →33 of the 126 studies in Stress Disorders, Post-Traumatic with a site in Canada are open now. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 18–65
COMPASS Pathways · Sites in Canada, United States
Ages 18+
Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18+
University of British Columbia · Sites in Canada
Ages 19+ · Women only
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 22 · Phase 3 8 · Phase 4 2
First in 2007; this study’s year is marked. 16 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 69 across 2,199 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 54 across the 112 interventional studies, 303 across the 14 observational. Of the 65 that completed or were terminated, 6 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 126 have an industry lead sponsor. The 10 most frequent:
The Royal Ottawa Mental Health Centre is the lead sponsor of 23 studies on the registry; 17 are open to participants now.
The Royal Ottawa Mental Health Centre has 1 study filed under Stress Disorders, Post-Traumatic — fewer than ten, so there is no comparison to draw.
7 of the studies in Stress Disorders, Post-Traumatic with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07137845Université de SherbrookeVirtual Reality and Cranial Nerve Non-invasive Neuromodulation to Improve Quality of Life for Veterans | 2026-12 |
| NCT07309302Université du Québec a MontréalPsychosocial Factors and Efficacy of Remote Cognitive Remediation for Post-Traumatic Stress Disorder | 2026-12 |
| NCT07146633Centre for Addiction and Mental HealthEfficacy of an EMDR App for PTSD and SUD | 2027-01-30 |
| NCT06044675RemedyMDMA-Assisted CBCT for PTSD vs CBCT RCT | 2027-03-31 |
| NCT06335043London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sPersonalized Pharmacotherapy Using Pharmacogenetics in Veterans | 2027-04-25 |
Add all 7 to your calendar (.ics) → With an account.
Among the 126 studies in Stress Disorders, Post-Traumatic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine the effects of a clinical treatment called deep brain reorienting (DBR) on post-traumatic stress disorder (PTSD).
We will be investigating if DBR helps reduce PTSD symptoms. To do so, we will be assigning participants to either receive DBR or continue with their current treatment. By comparing the results from the two groups, we will learn if DBR could be an effective treatment for PTSD.
Participants will be randomly assigned (e.g., like the flip of a coin) to receive either eight weekly sessions of DBR treatment or continue with their current treatment. Participants assigned to continue with their current treatment will be offered eight DBR sessions after they have completed the study.
The study will take place online/virtually over video conferencing.
This study is a randomized controlled preliminary feasibility trial designed to evaluate the effectiveness of Deep Brain Reorienting (DBR) in reducing PTSD symptoms. DBR was designed by Frank Corrigan, a clinician and scientist interested in the brain mechanisms underlying effective trauma psychotherapy. Study participation will include randomization to either the DBR treatment or treatment-as-usual (TAU) study groups and psychological assessments.
Potential participants will complete an initial screening interview to rule out any obvious exclusions. Individuals that meet preliminary eligibility criteria will be scheduled for an informed consent session. Those who meet criteria for inclusion will be scheduled for a baseline clinical assessment. If appropriate for the study, they will be randomized to one of 2 treatment groups, DBR or TAU. Treatment will entail 8 sessions of DBR, or 8 weeks of TAU (i.e., conventional treatment). After treatment/TAU is complete, a post-treatment assessment interview will take place. Finally, 3 months post-treatment/post-TAU end, a third assessment interview will be completed. For those in the TAU group, 8 sessions of DBR will be offered at this point.
DBR sessions will take place virtually using video conferencing. Short pre/post session questionnaires and ratings will be completed each week to help track the participant's mental state. Bi-weekly pre-session self-report questionnaires will be completed to assess changes in the participant's PTSD symptoms and dissociative experiences. Participants in the TAU group will complete bi-weekly check-ins with a research staff member on weeks 2, 4, 6, and 8 over video conferencing. The check-in sessions are intended to support study retention and ensure that participants have some contact with study staff during their 8-week TAU phase
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical
Psychological/Psychiatric
Legal Status
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomly assigned to the DBR group will be asked to attend eight, 50-minute, one-on-one sessions of DBR with a therapist.
Behavioral: Deep Brain Reorienting (DBR)
Participants randomly assigned to the TAU group will continue to receive the ongoing conventional treatment that they are currently being provided for 8 weeks (the equivalent time for 8 sessions of DBR in the treatment group).
Behavioral: Treatment-as-usual (TAU)
DBR involves bringing up a traumatic memory; however, instead of focusing on the emotions or specific events, participants are asked to attend to the muscles in the shoulders, neck, head, and face. These muscles are engaged when attending to stimuli in the environment, including potentially threatening or frightening situations. The DBR therapist guides participants to maintain this focus and provides support to help regulate the central nervous system as needed throughout the session.
The TAU condition is intended as a naturalistic usual-care comparison, reflecting the care participants are receiving at the time of enrolment. Participants who are already receiving eligible supportive counselling or other non-trauma-focused therapy may continue that treatment during the 8-week TAU period. Participants who are not receiving treatment at enrolment will not be assigned treatment by the study; for these participants, a period without treatment reflects their usual care at the time of enrolment. TAU treatment is not provided or directed by study therapists. TAU participants will be offered eight sessions of DBR after completing the three-month follow-up assessment interview.
Change in clinician-assessed PTSD symptoms from baseline as measured by the Clinician-Administered PTSD Scale-5 (CAPS-5) at the post-treatment assessment.
The CAPS-5 symptom severity score ranges from 0-80, with higher scores representing greater PTSD symptoms.
Time frame: From baseline to post-treatment, 8 weeks
Change in clinician-assessed PTSD symptoms from baseline as measured by the Clinician-Administered PTSD Scale-5 (CAPS-5) at the three-month follow-up assessment.
The CAPS-5 symptom severity score ranges from 0-80, with higher scores representing greater PTSD symptoms.
Time frame: From baseline to three-month post-treatment follow-up, 5 months
Change in self-reported PTSD symptoms from baseline as measured by the PTSD Checklist for DSM-5 (PCL-5) at the post-treatment assessment.
The PCL-5 symptom severity score ranges from 0-80, with higher scores representing greater PTSD symptoms.
Time frame: From baseline to post-treatment, 8 weeks
Change in self-reported PTSD symptoms from baseline as measured by the PTSD Checklist for DSM-5 (PCL-5) at the three-month follow-up assessment.
The PCL-5 symptom severity score ranges from 0-80, with higher scores representing greater PTSD symptoms.
Time frame: From baseline to three-month post-treatment follow-up, 5 months
Change in self-reported depressive symptoms from baseline as measured by the Beck Depression Inventory-II (BDI-II) at the post-treatment assessment.
The BDI-II score ranges from 0-63, with higher scores indicating more severe depression symptoms.
Time frame: From baseline to post-treatment, 8 weeks
Change in self-reported depressive symptoms from baseline as measured by the Beck Depression Inventory-II (BDI-II) at the three-month follow-up assessment.
The BDI-II score ranges from 0-63, with higher scores indicating more severe depression symptoms.
Time frame: From baseline to three-month post-treatment follow-up, 5 months
Change in self-reported dissociative experiences from baseline as measured by the Dissociative Experiences Scale (DES) at the post-treatment assessment.
The DES score ranges from 0-100, with higher scores indicating greater levels of dissociative experiences.
Time frame: From baseline to post-treatment, 8 weeks
Change in self-reported dissociative experiences from baseline as measured by the Dissociative Experiences Scale (DES) at the three-month follow-up assessment
The DES score ranges from 0-100, with higher scores indicating greater levels of dissociative experiences.
Time frame: From baseline to three-month post-treatment follow-up, 5 months
Change in self-reported physical symptoms from baseline as measured by the Physical Symptoms Scale (PSS) at the post-treatment assessment.
The PSS score ranges from 0-33, with higher scores indicating more severe physical symptoms.
Time frame: From baseline to post-treatment, 8 weeks
Change in self-reported physical symptoms from baseline as measured by the Physical Symptoms Scale (PSS) at the three-month follow-up assessment.
The PSS score ranges from 0-33, with higher scores indicating more severe physical symptoms.
Time frame: From baseline to three-month post-treatment follow-up, 5 months
Change in self-reported trauma-related shame from baseline as measured by the Trauma-Related Shame Inventory (TRSI) at the post-treatment assessment.
The TRSI score ranges from 0-72, with higher scores indicating greater levels of trauma-related shame.
Time frame: From baseline to post-treatment, 8 weeks
Change in self-reported trauma-related shame from baseline as measured by the Trauma-Related Shame Inventory (TRSI) at the three-month follow-up assessment.
The TRSI score ranges from 0-72, with higher scores indicating greater levels of trauma-related shame.
Time frame: From baseline to three-month post-treatment follow-up, 5 months
Change in self-reported interoceptive awareness from baseline as measured by the Multidimensional Assessment of Interoceptive Awareness-Version 2 (MAIA-V2) at the post-treatment assessment.
The MAIA-V2 consists of 37 items comprising eight subscales. Higher scores on the MAIA-V2 subscales indicate greater interoceptive awareness.
Time frame: From baseline to post-treatment, 8 weeks
Change in self-reported interoceptive awareness from baseline as measured by the Multidimensional Assessment of Interoceptive Awareness-Version 2 (MAIA-V2) at the three-month follow-up assessment.
The MAIA-V2 consists of 37 items comprising eight subscales. Higher scores on the MAIA-V2 subscales indicate greater interoceptive awareness.
Time frame: From baseline to three-month post-treatment follow-up, 5 months
Plan to share: No — Individual participant data (IPD) will not be made available to external researchers. De-identified participant data (e.g., questionnaire responses) will only be shared with co-investigators and collaborators at Western University and the University of Alberta to complete analyses for the project. Data sharing agreements will be obtained to share de-identified data between these institutions. Participants will be made aware of this data sharing arrangement during the informed consent process.
Start is estimated for Dec 2026; primary completion for Jan 2028, 13 months later.
Of 1,065 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 13 months is below that.
Counting every sponsor, half of 1,093 studies reached it within 34 months; a quarter within 17 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stress Disorders, Post-Traumatic →
The Royal Ottawa Mental Health Centre